acute kidney injury
![AM-Pharma lays off staff and changes CEO after failed phase 3 trial of ilofotase alfa](https://pharmtales.com/wp-content/uploads/2023/09/AM-Pharma-lays-off-staff-and-changes-CEO-after-failed-phase-3-trial-of-ilofotase-alfa.jpg)
AM-Pharma lays off staff and changes CEO after failed phase 3 trial of ilofotase alfa
Anika Sharma
After experiencing a setback in its phase 3 study for sepsis-associated acute kidney injury (SA-AKI), Dutch biotech company AM-Pharma is ...